Data from Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Autor: Udai Banerji, Johann S. de Bono, Stanley B. Kaye, L. Rhoda Molife, Timothy A. Yap, Marta Capelan, Karim Rihawi, Begona Jimenez, Elena Geuna, Desamparados Roda, Saeed Rafii

Purpose: Novel antitumor therapies against the PI3K–AKT–mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents are not known to be myelosu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::320b7e42897e6d957e72f275be463ae7
https://doi.org/10.1158/1078-0432.c.6522800

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study

Autor: Thierry Andre, Dominique Berton, Giuseppe Curigliano, Begona Jimenez-Rodriguez, Susan Ellard, Adriano Gravina, Rowan Miller, Anna Tinker, Andrea Jewell, Joanna Pikiel, Ana Oaknin, Tao Duan, Sybil Zildjian, Eleftherios Zografos, Jennifer Taylor Veneris, Susana N. Banerjee

Publikováno v: Journal of Clinical Oncology. 40:2587-2587

2587 Background: Dostarlimab is a programmed death 1 (PD-1) inhibitor approved in the US as a monotherapy in pts with dMMR solid tumors that have progressed on or after prior treatment, with no satisfactory alternative treatment options; or dMMR adva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ab8667fd744c738693df611830f132c
https://doi.org/10.1200/jco.2022.40.16_suppl.2587

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK

Autor: Udai Banerji, Peter Lawrence, Emma Dean, Ed Casson, Andrew Foxley, Emilie M.J. van Brummelen, Paul Rugman, Jan H.M. Schellens, Begona Jimenez, Matthew G Krebs, James W.T. Yates, Diana Cripps, Justin P.O. Lindemann, Guy Turner, Marie Cullberg, Taylor Nigel Phillip, Christopher Bailey, Stephen Evans

Publikováno v: Cancer Chemotherapy and Pharmacology
Dean, E, Banerji, U, Schellens, J H M, Krebs, M G, Jimenez, B, van Brummelen, E, Bailey, C, Casson, E, Cripps, D, Cullberg, M, Evans, S, Foxley, A, Lindemann, J, Rugman, P, Taylor, N, Turner, G, Yates, J & Lawrence, P 2018, ' A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies : OAK ', Cancer Chemotherapy and Pharmacology, vol. 81, no. 5, pp. 873-883 . https://doi.org/10.1007/s00280-018-3558-z

PURPOSE: AZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect of food (P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90253448509ce92049483870d5e60b4b
https://doi.org/10.1007/s00280-018-3558-z

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis

Autor: Luis Vicioso, Frank Holtrup, Begoña Bermejo, Frederick S. Jones, Johannes Fredebohm, Begona Jimenez Rodriguez, Matthew B. Ryder, Martina Alvarez, Emilio Alba, Alicia Garrido Aranda, Casilda Llacer Perez, Cristina Hernando, Ana Julve Parreño, Ana Lluch, Gema Diaz Córdoba, María Isabel Queipo-Ortuño

Publikováno v: Journal of Clinical Medicine
Volume 8
Issue 8
Journal of Clinical Medicine, Vol 8, Iss 8, p 1183 (2019)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Circulating tumor DNA (ctDNA) has emerged as a non-invasive &ldquo
liquid biopsy&rdquo
for early breast cancer diagnosis. We evaluated the suitability of ctDNA analysis in the diagnosis of early breast cancer after mammography findings, com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47fb9e4ff371332cda70f20ab96382d5
https://hdl.handle.net/10668/14381